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Available online 27 April 2014A 52-year-old French woman without medical history had
developed right foot pruritus three days after a prolonged
barefoot walk on a beach in Rio de Janeiro, Brazil. She con-
sulted with a local physician, who made a clinical diagnosis
of cutaneous larva migrans. She was subsequently started on
albendazole 400 mg  daily for ﬁve days.
After an initial improvement, symptoms recurred and
worsened on day 4 of treatment, without iterative exposure
to contaminated soil.
She subsequently went back to France and presented with
an itchy, erythematous serpiginous eruption on the sole of her
right foot (Fig. 1), consistent with the diagnosis of cutaneous
larva migrans.
Primary resistance to albendazole was suspected, and she
was therefore given ivermectin 200 g/kg as a single-dose. Ten
days later, a marked regression of cutaneous signs was seen,
and the patient reported a full regression of pruritus. No recur-
rence was seen with a follow-up of three months.Albendazole and ivermectin are two drugs of choice in
the treatment of cutaneous larva migrans. Although a sin-
gle dose of albendazole is less effective than a single dose of
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ivermectin, a 5–7 days of oral albendazole (400 mg  daily) is
considered to be an effective alternative in countries without
ivermectin.2 In our case, ivermectin was a better option for the
treatment of the infection.
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